

# Barbara Ruozi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3545132/publications.pdf>

Version: 2024-02-01

115  
papers

4,105  
citations

117453

34  
h-index

133063

59  
g-index

119  
all docs

119  
docs citations

119  
times ranked

6150  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tunneling Nanotubes: A New Target for Nanomedicine?. International Journal of Molecular Sciences, 2022, 23, 2237.	1.8	11
2	Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines. Polymers, 2022, 14, 687.	2.0	33
3	Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments. Pharmaceutics, 2022, 14, 1450.	2.0	7
4	Curcumin Loaded Polymeric vs. Lipid Nanoparticles: Antioxidant Effect on Normal and Hypoxic Olfactory Ensheathing Cells. Nanomaterials, 2021, 11, 159.	1.9	17
5	Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. Journal of Controlled Release, 2021, 330, 587-598.	4.8	33
6	Microfluidic Technology for the Production of Hybrid Nanomedicines. Pharmaceutics, 2021, 13, 1495.	2.0	9
7	Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations. Pharmaceutics, 2021, 14, 943.	1.7	1
8	Nanomedicines for brain diseases: where we are and where we are going. Therapeutic Delivery, 2021, 12, 631-635.	1.2	1
9	Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer. ACS Omega, 2021, 6, 2973-2989.	1.6	30
10	Tween® Preserves Enzyme Activity and Stability in PLGA Nanoparticles. Nanomaterials, 2021, 11, 2946.	1.9	11
11	Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function. Molecules, 2020, 25, 4593.	1.7	14
12	Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment. Frontiers in Pharmacology, 2020, 11, 574.	1.6	21
13	Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102226.	1.7	20
14	Development, Optimization and Characterization of Eudraguard®-Based Microparticles for Colon Delivery. Pharmaceutics, 2020, 13, 131.	1.7	7
15	PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study. Pharmaceutics, 2020, 12, 72.	2.0	46
16	Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization. Pharmaceutics, 2020, 12, 339.	2.0	11
17	Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications. Polymers, 2020, 12, 823.	2.0	16
18	Nanomedicine Against A $\beta$ 2 Aggregation by $\beta$ -Sheet Breaker Peptide Delivery: In Vitro Evidence. Pharmaceutics, 2019, 11, 572.	2.0	18

#	ARTICLE	IF	CITATIONS
19	ROS-responsive smart-polymeric conjugate: Synthesis, characterization and proof-of-concept study. <i>International Journal of Pharmaceutics</i> , 2019, 570, 118655.	2.6	31
20	Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2014.	1.8	47
21	Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy. <i>Progress in Brain Research</i> , 2019, 245, 57-88.	0.9	39
22	Antioxidant activity and photostability assessment of trans-resveratrol acrylate microspheres. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 222-234.	1.1	13
23	In vitro treatment of congenital disorder of glycosylation type Ia using PLGA nanoparticles loaded with GDP-Man. <i>International Journal of Molecular Medicine</i> , 2019, 44, 262-272.	1.8	4
24	Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles. <i>Nanomedicine</i> , 2018, 13, 407-422.	1.7	11
25	Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer's disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 49, 210-221.	1.5	64
26	Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain. <i>International Journal of Pharmaceutics</i> , 2018, 543, 300-310.	2.6	26
27	Translational potential of cholesterol supplementation-based strategies for huntington's disease. , 2018, , .		1
28	Protein corona and nanoparticles: how can we investigate on?. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1467.	3.3	93
29	Apo ferritin nanocage as streptomycin drug reservoir: Technological optimization of a new drug delivery system. <i>International Journal of Pharmaceutics</i> , 2017, 518, 281-288.	2.6	14
30	Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders. <i>International Review of Neurobiology</i> , 2017, 137, 1-28.	0.9	27
31	Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 107, 230-239.	1.9	23
32	Protein cage nanostructure as drug delivery system: magnifying glass on apo ferritin. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 825-840.	2.4	47
33	Identifying a therapeutic regimen for cholesterol delivery to huntington's disease brain. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A95.2-A95.	0.9	0
34	Synthesis, characterization and in vitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides. <i>European Journal of Medicinal Chemistry</i> , 2016, 120, 329-337.	2.6	6
35	Preparation, characterization and photostability assessment of curcumin microencapsulated within methacrylic copolymers. <i>Journal of Drug Delivery Science and Technology</i> , 2016, 33, 88-97.	1.4	22
36	EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION. <i>International Journal of Pharmaceutics</i> , 2016, 511, 331-340.	2.6	18

#	ARTICLE	IF	CITATIONS
37	Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. <i>Pharmacological Research</i> , 2016, 111, 713-720.	3.1	84
38	Apo ferritin nanocage as drug reservoir: is it a reliable drug delivery system?. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1341-1343.	2.4	16
39	Nanoimaging: photophysical and pharmaceutical characterization of poly-lactide-co-glycolide nanoparticles engineered with quantum dots. <i>Nanotechnology</i> , 2016, 27, 015704.	1.3	4
40	Nanoparticle transport across the blood brain barrier. <i>Tissue Barriers</i> , 2016, 4, e1153568.	1.6	121
41	PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 99, 7-17.	2.0	17
42	The "fate" of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood-brain barrier crossing and trafficking into the central nervous system. <i>Journal of Drug Delivery Science and Technology</i> , 2016, 32, 66-76.	1.4	58
43	Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders. <i>PLoS ONE</i> , 2016, 11, e0156452.	1.1	72
44	Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1079-1091.	0.8	8
45	Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. <i>EMBO Molecular Medicine</i> , 2015, 7, 1547-1564.	3.3	84
46	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. <i>Haematologica</i> , 2015, 100, e467-e470.	1.7	9
47	Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. <i>Pharmaceutics</i> , 2015, 7, 74-89.	2.0	46
48	Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma. <i>International Journal of Pharmaceutics</i> , 2015, 490, 85-93.	2.6	10
49	PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. <i>Nanomedicine</i> , 2015, 10, 1735-1750.	1.7	60
50	Nanomedicine and neurodegenerative disorders: so close yet so far. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1041-1044.	2.4	15
51	PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury. <i>Molecular Neurobiology</i> , 2015, 52, 899-912.	1.9	57
52	Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): <i>In Vivo</i> Experiments. <i>Molecular Pharmaceutics</i> , 2015, 12, 3672-3684.	2.3	36
53	Functionalization of liposomes: microscopical methods for preformulative screening. <i>Journal of Liposome Research</i> , 2015, 25, 150-156.	1.5	6
54	Preparation and Microbiological Evaluation of Amphiphilic Kanamycin-Lipoamino Acid Ion-Pairs. <i>Antibiotics</i> , 2014, 3, 216-232.	1.5	4

#	ARTICLE	IF	CITATIONS
55	Sustained Zero-Order Release of Intact Ultra-Stable Drug-Loaded Liposomes from an Implantable Nanochannel Delivery System. <i>Advanced Healthcare Materials</i> , 2014, 3, 230-238.	3.9	48
56	Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. <i>Journal of Controlled Release</i> , 2014, 174, 195-201.	4.8	63
57	Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport. <i>Journal of Controlled Release</i> , 2014, 177, 96-107.	4.8	48
58	Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release. <i>International Journal of Pharmaceutics</i> , 2014, 471, 349-357.	2.6	17
59	Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy. <i>International Journal of Nanomedicine</i> , 2014, 9, 2791.	3.3	18
60	Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'. <i>Current Medicinal Chemistry</i> , 2014, 21, 4169-4185.	1.2	20
61	Poly (D,L-Lactide-co-Glycolide) Nanoparticles Loaded with Cerebrolysin Display Neuroprotective Activity in a Rat Model of Concussive Head Injury. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1475-1482.	0.8	21
62	Nanoparticles as Blood-Brain Barrier Permeable CNS Targeted Drug Delivery Systems. <i>Topics in Medicinal Chemistry</i> , 2013, , 71-89.	0.4	22
63	Brain targeting with polymeric nanoparticles: which administration route should we take?. <i>Nanomedicine</i> , 2013, 8, 1361-1363.	1.7	16
64	AFM and TEM characterization of siRNAs lipoplexes: A combinatory tools to predict the efficacy of complexation. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2013, 436, 459-466.	2.3	11
65	Biodegradable device applied in flatfoot surgery: Comparative studies between clinical and technological aspects of removed screws. <i>Materials Science and Engineering C</i> , 2013, 33, 1773-1782.	3.8	12
66	Brain-targeted polymeric nanoparticles: <i>in vivo</i> evidence of different routes of administration in rodents. <i>Nanomedicine</i> , 2013, 8, 1373-1383.	1.7	26
67	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. <i>Clinical Cancer Research</i> , 2013, 19, 3871-3880.	3.2	30
68	Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier. <i>Current Medicinal Chemistry</i> , 2013, 20, 2212-2225.	1.2	113
69	Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 <sup>wildtype</sup> ; JVM-2 But Not Towards p53 <sup>mutated</sup> ; BJAB Leukemic Cells. <i>Current Medicinal Chemistry</i> , 2013, 20, 2712-2722.	1.2	12
70	The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier. <i>Drug Delivery</i> , 2012, 19, 1-10.	2.5	16
71	Nanomedicine: the future for advancing medicine and neuroscience. <i>Nanomedicine</i> , 2012, 7, 1113-1116.	1.7	21
72	Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. <i>International Journal of Pharmaceutics</i> , 2012, 436, 753-763.	2.6	25

#	ARTICLE	IF	CITATIONS
73	Neurotrophic Factors and Neurodegenerative Diseases. <i>International Review of Neurobiology</i> , 2012, 102, 207-247.	0.9	26
74	Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?. <i>Nanomedicine</i> , 2012, 7, 365-382.	1.7	44
75	Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. <i>European Journal of Medicinal Chemistry</i> , 2012, 49, 110-117.	2.6	75
76	Application of poly-L-lactide screws in flat foot surgery: histological and radiological aspects of bio-absorption of degradable devices. <i>Histology and Histopathology</i> , 2012, 27, 485-96.	0.5	8
77	The Bridge Between Nanotechnology and Neuroscience: Neuro-Nanomedicine. <i>Journal of Nanoneuroscience</i> , 2012, 2, 20-26.	0.5	2
78	Immunonanosystems to CNS Pathologies. , 2012, , 107-168.		0
79	The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against <i>Cryptosporidium parvum</i> . <i>Parasitology</i> , 2011, 138, 1384-1391.	0.7	7
80	Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. <i>Nanomedicine</i> , 2011, 6, 423-436.	1.7	80
81	Development of Novel Zn <sup>2+</sup> Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences. <i>PLoS ONE</i> , 2011, 6, e17851.	1.1	46
82	AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study. <i>International Journal of Nanomedicine</i> , 2011, 6, 557.	3.3	150
83	Amphiphilic Erythromycin-Lipoamino Acid Ion Pairs: Characterization and In Vitro Microbiological Evaluation. <i>AAPS PharmSciTech</i> , 2011, 12, 468-475.	1.5	16
84	NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. <i>Journal of Neural Transmission</i> , 2011, 118, 145-153.	1.4	45
85	Amphiphilic ion pairs of tobramycin with lipoamino acids. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 1665-1671.	2.6	17
86	Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: Preparation, characterization and comparative in vitro study with polymeric particles and liposomes. <i>International Journal of Pharmaceutics</i> , 2011, 413, 220-228.	2.6	10
87	Sialic acid as a potential approach for the protection and targeting of nanocarriers. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 921-937.	2.4	31
88	Nanoparticles for Brain Delivery of Drugs: In vivo Experiments and Mechanism of Blood-Brain Barrier Crossing. <i>American Journal of Neuroprotection and Neuroregeneration</i> , 2011, 3, 13-20.	0.1	2
89	Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. <i>Journal of Controlled Release</i> , 2010, 145, 49-57.	4.8	110
90	Cidofovir-loaded liposomes: an in vitro study using BCBL-1 cell line as a model for primary effusion lymphoma. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 254-264.	1.9	16

#	ARTICLE	IF	CITATIONS
91	pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2010, 389, 254-261.	2.6	57
92	Immunoliposomal systems targeting primary effusion lymphoma: <i>in vitro</i> study. <i>Nanomedicine</i> , 2010, 5, 1051-1064.	1.7	8
93	Nuclear localization of cationic solid lipid nanoparticles containing Protamine as transfection promoter. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 76, 384-393.	2.0	23
94	Collagen-based modified membranes for tissue engineering: Influence of type and molecular weight of GAGs on cell proliferation. <i>International Journal of Pharmaceutics</i> , 2009, 378, 108-115.	2.6	25
95	Colloidal systems for CNS drug delivery. <i>Progress in Brain Research</i> , 2009, 180, 35-69.	0.9	32
96	AFM phase imaging of soft-hydrated samples: A versatile tool to complete the chemical-physical study of liposomes. <i>Journal of Liposome Research</i> , 2009, 19, 59-67.	1.5	25
97	Flow cytometry and live confocal analysis for the evaluation of the uptake and intracellular distribution of FITC-ODN into HaCaT cells. <i>Journal of Liposome Research</i> , 2009, 19, 241-251.	1.5	6
98	Glycopeptide-Decorated Nanoparticles as Drug Carriers for CNS: Effects of Surface Coverage and Carbohydrate Type. <i>Journal of Nanoneuroscience</i> , 2009, 1, 152-157.	0.5	0
99	Polymeric nanoparticles for the drug delivery to the central nervous system. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 155-174.	2.4	189
100	Application of atomic force microscopy to characterize liposomes as drug and gene carriers. <i>Talanta</i> , 2007, 73, 12-22.	2.9	78
101	Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: Characterization and ability to bind the pEGFP-plasmid. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 67, 320-328.	2.0	61
102	Intact collagen and atelocollagen sponges: Characterization and ESEM observation. <i>Materials Science and Engineering C</i> , 2007, 27, 802-810.	3.8	13
103	Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. <i>Journal of Controlled Release</i> , 2007, 122, 1-9.	4.8	217
104	DOTAP/UDCA vesicles: novel approach in oligonucleotide delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2007, 3, 1-13.	1.7	12
105	PLA-microparticles formulated by means a thermoreversible gel able to modify protein encapsulation and release without being co-encapsulated. <i>International Journal of Pharmaceutics</i> , 2006, 323, 131-138.	2.6	30
106	PLA/PLGA nanoparticles for sustained release of docetaxel. <i>International Journal of Pharmaceutics</i> , 2006, 325, 172-179.	2.6	383
107	Vegetable cells in Papanicolaou-stained cervical smears. <i>Diagnostic Cytopathology</i> , 2006, 34, 45-49.	0.5	10
108	Atomic force microscopy and photon correlation spectroscopy: Two techniques for rapid characterization of liposomes. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 81-89.	1.9	112

#	ARTICLE	IF	CITATIONS
109	Liposome-oligonucleotides interaction for in vitro uptake by COS I and HaCaT cells. Journal of Drug Targeting, 2005, 13, 295-304.	2.1	9
110	Ketorolac Tromethamine Liposomes: Encapsulation and Release Studies. Journal of Liposome Research, 2005, 15, 175-185.	1.5	18
111	Cationic Liposomes for Gene Transfection. Journal of Drug Targeting, 2003, 11, 407-414.	2.1	36
112	Comparison between Roesy and <sup>13</sup> C NMR Complexation Shifts in Deriving the Geometry of Inclusion Compounds: A Study on the Interaction between Hyodeoxycholic Acid and 2-Hydroxypropyl-β-Cyclodextrin. Supramolecular Chemistry, 2001, 12, 427-433.	1.5	8
113	Title is missing!. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2000, 37, 237-251.	1.6	16
114	Evidence of the Existence of 2:1 Guest-Host Complexes between Diclofenac and Cyclodextrins in D2O Solutions. A 1H and 13C NMR Study on Diclofenac/β-Cyclodextrin and Diclofenac/2-Hydroxypropyl-β-cyclodextrin Systems. Journal of Chemical Research Synopses, 1999, , 414-415.	0.3	13
115	Nanotechnology for Drug Targeting. Advances in Science and Technology, 0, , .	0.2	0